ASH 2023 | Advancements in AML: an update from ASH 2023
Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY, discusses her highlights from ASH 2023 in the realm of acute myeloid leukemia (AML), including advancements in menin inhibitors, triplet combinations with quizartinib, IDH inhibitors, and utilizing MRD status to predict survival outcomes in FLT3-mutated AML. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Current holder of stock options: Reata Pharmaceuticals
Patents & Royalties: Reata Pharmaceuticals
Consultancy: AbbVie, AstraZeneca, Genentech, Gilead, Janssen, MEI Pharma, Sanofi Aventis, Stemline-Menarini, Vincerx
Research Funding: AbbVie, Ablynx, Allogene, AstraZeneca, Cellectis, Daiichi, FortySeven, Genentech, Gilead, Immunogen, MEI Pharma, Precision Biosciences, Rafael Pharmaceutical, Sanofi Aventis, Stemline-Menarini
